Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer

(2018) Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology. pp. 1478-1485. ISSN 0002-9440

Full text not available from this repository.

Abstract

Antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-L1) interaction have shown clinical activity in multiple cancer types. PD-L1 protein expression is a clinically validated predictive biomarker of response for such therapies. Prior studies evaluating the expression of PD-L1 in primary prostate cancers have reported highly variable rates of PD-L1 positivity. In addition, limited data exist on PD-L1 expression in metastatic castrate-resistant prostate cancer (mCRPC). Here, we determined PD-L1 protein expression by immunohistochemistry using a validated PD-L1specific antibody (SP263) in a large and representative cohort of primary prostate cancers and prostate cancer metastases. The study included 539 primary prostate cancers comprising 508 acinar adenocarcinomas, 24 prostatic duct adenocarcinomas, 7 small-cell carcinomas, and a total of 57 cases of mCRPC. PD-L1 positivity was low in primary acinar adenocarcinoma, with only 7.7 of cases showing detectable PD-L1 staining. Increased levels of PD-L1 expression were noted in 42.9 of small-cell carcinomas. In mCRPC, 31.6 of cases showed PD-L1specific immunoreactivity. In conclusion, in this comprehensive evaluation of PD-L1 expression in prostate cancer, PD-L1 expression is rare in primary prostate cancers, but increased rates of PD-L1 positivity were observed in mCRPC. These results will be important for the future clinical development of programmed cell death protein 1/PD-L1targeting therapies in prostate cancer.

Item Type: Article
Keywords: cell lung-cancer adaptive immune resistance pd-l1 expression mutational landscape blockade immunotherapy abiraterone antibody enzalutamide genomics
Divisions: Faculty of Medicine > Departments of Clinical Sciences > Department of Pathology
Isfahan Kidney Diseases Research Center
Page Range: pp. 1478-1485
Journal or Publication Title: American Journal of Pathology
Journal Index: ISI
Volume: 188
Number: 6
Identification Number: https://doi.org/10.1016/j.ajpath.2018.02.014
ISSN: 0002-9440
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/6615

Actions (login required)

View Item View Item